Sepracor’s board of directors has approved the appointment of Robert F. Scumaci as executive VP and CFO. Scumaci most recently served as executive VP, corporate finance, administration and technical operations at Sepracor, maker of Lunesta, a non-narcotic non-benzodiazepine indicated for the treatment of insomnia.

Scumaci assumed his new role on May 20, 2008, replacing David P. Southwell, who is resigning to pursue other interests but will remain a consultant to the company through the end of the year.

"I am very pleased to announce Bob’s appointment as our new Chief Financial Officer," said Adrian Adams, president and CEO of Sepracor. "Bob brings with him a wealth of skills in finance, administration and general management. Over the last 13 years, Bob has had a strong record of leadership and accomplishments at Sepracor and has recruited, developed and managed fully integrated accounting, finance, information technologies, human resources and facility engineering departments. We are embarking on a very exciting growth phase for the Company, and Bob will play an integral role in planning and executing our core strategy against the expectations we set."